Baird Medical Expands into San Francisco, Advancing U.S. Market Growth

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) announces expansion into San Francisco as part of its U.S. growth strategy, following its participation in the J.P. Morgan Health Conference. Dr. Terrence K. Trapp, an otolaryngologist, has integrated the company's Microwave Ablation (MWA) system into his practice.

Since receiving FDA 510(k) clearance in November 2023, the company has treated hundreds of U.S. patients with its MWA technology, reporting positive treatment outcomes. Notable adoption includes Dr. Emad Kandil at Tulane University, who has performed over 100 MWA procedures.

The company is focusing on expanding physician education and awareness of MWA technology through collaboration with medical specialists and comprehensive training support.

Positive

• FDA 510(k) clearance received in November 2023
• Successful treatment of hundreds of U.S. patients since FDA clearance
• Notable adoption by key medical professionals, with one physician performing over 100 procedures
• Geographic expansion into San Francisco market

Negative

• None.

News Market Reaction

+1.45%

1 alert

+1.45% News Effect

On the day this news was published, BDMD gained 1.45%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in minimally invasive Microwave Ablation (MWA) technology, is expanding its presence into San Francisco, marking an important step in its U.S. growth strategy. This expansion follows the recent J.P. Morgan Health Conference in San Francisco, highlighting the company's early success in executing its strategic vision for medical innovation.

As part of this development, Dr. Terrence K. Trapp, an experienced otolaryngologist, has integrated the Company's MWA system into his practice, suggesting growing interest and recognition of minimally invasive approaches for managing thyroid nodules.

Since receiving FDA 510(k) clearance in November 2023, Baird Medical has treated hundreds of patients in the United States with its MWA technology, all of whom have experienced significant recovery and positive treatment outcomes. This growing adoption is exemplified by physicians like Dr. Emad Kandil, Professor of Surgery and Ellis Hanna Chair at Tulane University, who has performed over 100 MWA procedures. His experience further underscores the clinical potential of this technology and the medical community's increasing recognition of Baird Medical's innovations.

By collaborating with medical specialists and offering comprehensive training and clinical support, Baird Medical is actively expanding physician education and awareness of MWA technology in the U.S. With its entry into San Francisco, the Company aims to further improve access to minimally invasive treatment options, benefiting both physicians and patients.

About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.

These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.

Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-expands-into-san-francisco-advancing-us-market-growth-302356850.html

SOURCE BDMD

FAQ

When did Baird Medical (BDMD) receive FDA 510(k) clearance for its MWA technology?

Baird Medical received FDA 510(k) clearance for its Microwave Ablation technology in November 2023.

How many MWA procedures has Dr. Kandil performed using BDMD's technology?

Dr. Emad Kandil at Tulane University has performed over 100 MWA procedures using Baird Medical's technology.

What is the latest market expansion announced by BDMD?

Baird Medical announced its expansion into the San Francisco market in January 2025.

How many patients has BDMD treated in the US since FDA clearance?

Baird Medical has treated hundreds of patients in the United States since receiving FDA clearance in November 2023.

Which medical conference did BDMD attend before its San Francisco expansion?

Baird Medical attended the J.P. Morgan Health Conference in San Francisco before announcing its expansion into the market.